Study of Platelet-rich Plasma in Treating Patients With Tibiofemoral Cartilage Degeneration

Not Applicable

Completed

• Conditions: Cartilage Degeneration
• Interventions: Biological: platelet rich plasma injection

• Registration Number: NCT01418755
• Lead Sponsor: Komzak Martin, M.D.

Brief Summary

Recently an articular cartilage repair has been given much attention in the orthopaedic field. Cartilage regeneration capacity is very limited. Optimal approach seems to be a delivery of natural growth factors. Autologous platelet-rich plasma (PRP) contains proliferative and chemoattractant growth factors. The objective of the present study was to determine if PRP can increase tibiofemoral cartilage regeneration and improve knee function.

Detailed Description

Fifty consecutive and strictly selected patients, affected by Grade II or III chondromalacia, underwent one year treatment (9 injections) with autologous PRP in a liquid form with 2,0 to 2,5-fold platelets concentration. Outcome measures included hte Lysholm, Tegner, IKDC, and Cincinnati scores. Magnetic resonance imaging was used to evaluate cartilage thickness and degree of degeneration.

Study Timeline

• Study Start: 2009-01
• Primary Completion: 2009-11
• Study Completion: 2011-07
• Study First Submitted: 2011-08-15
• Study First Submitted QC: 2011-08-16
• Study First Posted: 2011-08-17
• Status Verified: 2011-09
• Last Update Submitted: 2011-09-14
• Last Update Posted: 2011-09-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• isolated Grade II or Grade III nontraumatic chondromalacia according to Outerbridge grading scale

Exclusion Criteria

• Grade I (only softening) or Grade IV (exposed subchondral bone) tibiofemoral chondromalacia;
• patellofemoral chondral damage;
• associated intraarticular lesions confirmed during arthroscopy (menisci, ligaments, osteochondral defects);
• associated extraarticular lesions confirmed by magnetic resonance imaging (ligaments, tendons, bursae);
• lower limb axial deviation confirmed by whole leg weight-bearing radiograph; knee trauma in patients history;
• body mass index (BMI) higher than 35;
• hyaluronic acid intraarticular injection 6 months prior the arthroscopy and up to last follow-up control;
• steroids intraarticular injection 3 months prior the arthroscopy and up to last follow-up control;
• symptomatic slow acting drugs for osteoarthritis (SYSADOA) and/or non-steroidal anti-inflammatory drugs (NSAID) administration during the PRP treatment;
• systemic autoimmune rheumatic and/or polyarticular disease; gout, pseudogout and hyperuricaemia.
• Other exclusion criteria included: non-informed consent; treated knee injury during the PRP therapy; PRP injection cycle not completed; impediments to fill out the questionnaires; blood disease and/or immunosuppressant treatment and/or dicoumarol therapy; immunosuppressant and/or neoplastic and/or infectious diseases.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
platelet rich plasma injection	platelet rich plasma injection	Fifty consecutive and strictly selected patients, affected by Grade II or III chondromalacia, underwent one year treatment (9 injections) with autologous PRP in a liquid form with 2,0 to 2,5-fold platelets concentration. Outcome measures included the Lysholm, Tegner, IKDC, and Cincinnati scores. Magnetic resonance imaging was used to evaluate cartilage thickness and degree of degeneration.

Primary Outcome Measures

Name	Time	Method
Change of the width of cartilage in the knee joint assessed by magnetic resonance imaging before and after nine Platelets Rich Plasma injections.	11 months after first Platelets Rich Plasma injection	50 patients with Grade II or III chondromalatia in the knee joint, underwent one year treatment with autologous Platelets Rich Plasma. Magnetic resonance imaging was used to evaluate cartilage thickness and degree of degeneration before and after the treatement of nine Platelets Rich Plasma injection.

Secondary Outcome Measures

Name	Time	Method
Changes in the subjective and objective clinical outcomes before and after nine Platelets Rich Plasma injections.	11 months	50 patients with Grade II or III chondromalatia in the knee joint, underwent one year treatment with autologous Platelets Rich Plasma. To carefully assess the subjective and objective clinical outcomes, these questionnaires were used: Lysholm score, Tegner activity score, IKDC scores, and Cincinnati score. All these scores were recompleted 11 months after the beginning of the Platelets Rich Plasma injections.

Trial Locations

Locations (1)

Hospital Znojmo; 🇨🇿 Znojmo, Czech Republic